Trials / Completed
CompletedNCT02593188
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 264 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the proposed study is to acquire additional data (including the assessment of anti-rHuPH20 antibodies) on the long-term safety of HYQVIA and to assess the prescribed treatment regimens and treatment administration in routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HYQVIA | Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase |
Timeline
- Start date
- 2015-11-12
- Primary completion
- 2021-10-21
- Completion
- 2021-10-21
- First posted
- 2015-11-02
- Last updated
- 2022-10-18
Locations
30 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02593188. Inclusion in this directory is not an endorsement.